GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Frontage Holdings Corp (HKSE:01521) » Definitions » Beta

Frontage Holdings (HKSE:01521) Beta : 1.19 (As of May. 16, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Frontage Holdings Beta?

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2024-05-16), Frontage Holdings's Beta is 1.19.


Frontage Holdings Beta Historical Data

The historical data trend for Frontage Holdings's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Frontage Holdings Beta Chart

Frontage Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beta
Get a 7-Day Free Trial - - - 1.54 1.29

Frontage Holdings Semi-Annual Data
Dec16 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 1.78 1.54 1.27 1.29

Competitive Comparison of Frontage Holdings's Beta

For the Biotechnology subindustry, Frontage Holdings's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Frontage Holdings's Beta Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Frontage Holdings's Beta distribution charts can be found below:

* The bar in red indicates where Frontage Holdings's Beta falls into.



Frontage Holdings Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.


Frontage Holdings  (HKSE:01521) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Frontage Holdings Beta Related Terms

Thank you for viewing the detailed overview of Frontage Holdings's Beta provided by GuruFocus.com. Please click on the following links to see related term pages.


Frontage Holdings (HKSE:01521) Business Description

Traded in Other Exchanges
Address
700 Pennsylvania Drive, Exton, PA, USA, 19341
Frontage Holdings Corp is a contract research organization providing integrated, scientifically driven research, analytical and development services. Geographically the group operates in both PRC and North America. The services provided in the North American segment, include Bioanalytical, CMC, DMPK and Safety and Toxicology services in the USA and Canada. The service offered in PRC includes Bioanalytical, Bioequivalence and CMC services in the PRC. Further, it also provides bioanalytical services, which are offered throughout the drug discovery and development process both in the United States and China.

Frontage Holdings (HKSE:01521) Headlines

No Headlines